Myelogenous Leukemia

Also found in: Dictionary, Thesaurus, Medical.

myelogenous leukemia

[‚mī·ə′läj·ə·nəs lü′kē·mē·ə]

Myelogenous Leukemia


(myelocytic leukemia, myeloid granulocytic leukemia, or myelosis), a disease of the blood system characterized by the overproduction of immature granulocytes (myelocytes, promyelocytes, less often myelo-blasts) in the hematopoietic organs.

In myelogenous leukemia, the number of leukocytes in the blood increases—in the initial period, up to 20,000 per micro-liter; in advanced stages, the number of leukocytes may reach 200,000 to 400,000 per microliter. Hemograms and myelograms show a predominance of cells of the granulocytic series (of varying degree of maturity: stab neutrophils, metamyelocytes, myelocytes, and promyelocytes). A distinguishing feature of these cells during myelogenous leukemia is change in the 21st and 22nd pairs of chromosomes. The percentage of basophils and eosinophils in the blood often increases, which indicates a more severe course of the disease. In the majority of cases there is an enlarged spleen. The disease progresses steadily. The terminal stage is characterized by emaciation, anemia, and the appearance of a large number of myeloblasts in the bone marrow and the blood.

Treatment includes chemotherapy, radiation therapy, general restorative therapy, and, when necessary, blood transfusion.


Kassirskii, I. A., and G. A. Alekseev. Klinicheskaia gematologiia, 4th ed. Moscow, 1970.


References in periodicals archive ?
Imatinib Mesylate has accurate curative effects on chronic myelogenous leukemia despite its relatively high price.
About 90 percent of chronic myelogenous leukemia patients treated with imatinib survive for 5 years or longer.
The IOM's subsequent review of the evidence found there is "inadequate or insufficient evidence" to establish a connection between the parent's Agent Orange exposure and development of acute myelogenous leukemia.
The incidence rate of acute myelogenous leukemias (AMLs) in the United States is approximately 2.
GlobalData, the industry analysis specialist, has released its new report, Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017.
Acute myelogenous leukemia develops when there's a defect in the immature cells in the bone marrow.
That changed when other scientists showed that the drug imatinib mesylate, or Gleevec, can thwart chronic myelogenous leukemia in animals and people by inhibiting another mutant tyrosine kinase (SN: 12/11/99, p.
com/research/f4ffea/acute_lymphoblasti) has announced the addition of the "Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report" report to their offering.
Study Evaluated Preliminary Efficacy of Venetoclax in 32 Patients with Relapsed/Refractory Acute Myelogenous Leukemia and as Frontline Therapy in Patients Unfit for Intensive Treatment
Friday's event was the 10th reunion for Pasadena resident Richard Myers, who had a transplant in 1994 in his battle against acute myelogenous leukemia.
The medicine known commercially as Gleevec serves as a powerful weapon for people fighting the blood cancer called chronic myelogenous leukemia, or CML.
Administration of the PR1 vaccine to some patients elicits the proliferation of, PR1-specific cytotoxic T lymphocytes that selectively kill three types of leukemia - myelodysplastic syndrome, acute myelogenous leukemia and chronic myelogenous leukemia.